Quince Therapeutics

Company snapshot

Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. Our Phase 3 lead asset, EryDex, is the first product in development that leverages our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated pr

• 10 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 10 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Quince Therapeutics. Not investment advice.

• Peer + 0 momentum

  Takeda

  TA overlap score 40

• Peer + 0 momentum

  Lakefront Biotherapeutics NV

  TA overlap score 39.8

• Peer + 0 momentum

  AbbVie

  TA overlap score 28.2

Recent activity

Latest pipeline, patent, and corporate events for Quince Therapeutics.

1. Jun 8, 2026 Clinical update

   IEDAT-04-2022 — Phase 3

2. Jun 8, 2026 Clinical update

   DSP loaded RBC using EryDex System — Phase 1

3. Jun 8, 2026 Clinical update

   Dex 21-P — Phase 2

4. Jun 5, 2026 Clinical update

   EryDex Low dose DSP — Phase 3

5. May 26, 2026 Clinical update

   Dexamethasone sodium phosphate for encapsulation into autoerythrocytes — Phase 3

View all clinical trial activity →

• What is Quince Therapeutics?

  Quince Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker QNCX. Primary therapeutic focus areas include Ataxia Telangiectasia, Ataxia Telangiectasia (A-T), Ulcerative Colitis, Crohn's Disease, Nervous System Disorder.

• Is Quince Therapeutics publicly traded?

  Yes. Quince Therapeutics is listed with ticker QNCX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Quince Therapeutics develop or market?

  We link 8 drug profile(s) where Quince Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/quince-therapeutics#company-drugs.

• What are the latest developments for Quince Therapeutics?

  In the last 12 months our linked public records show 10 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Quince Therapeutics focus on?

  Quince Therapeutics focuses on Ataxia Telangiectasia, Ataxia Telangiectasia (A-T), Ulcerative Colitis based on our analysis of their pipeline programs and drug development activities.